drugset / Trial / NCT03818542
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who are candidates for surgical resection.
Timeline
- Start
- 2020-01-22
- Primary completion
- 2020-09-23
- Completion
- 2020-09-23
Outcome
Outcome not reported
Stopped (Business): “Strategic considerations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budigalimab | Monoclonal antibody | — | Intravenous |
| Subject | GILORALIMAB | Monoclonal antibody | — | Intravenous |
| Subject | REVDOFILIMAB | Monoclonal antibody | — | Intravenous |